This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to
evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with
Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to
treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy
will be assessed as the proportion of subjects achieving complete clearance of all treatable
molluscum lesions (baseline and new) on the Day 84 visit.
Phase:
Phase 3
Details
Lead Sponsor:
Verrica Pharmaceuticals Inc.
Collaborators:
Database Integrations, Inc. Instat Consulting, Inc. Paidion Research, Inc.